Last reviewed · How we verify
NCT00967447
Study to Evaluate the Safety and Efficacy of Pradaxar for the Prevention of Venous Thromboembolism in the Mexican Population Undergoing Elective Total Hip or Knee Replacement Surgery
trial in Thromboembolism in 2 participants. Terminated before completion.
1 January 2010
Quick facts
| Lead sponsor | Boehringer Ingelheim |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 2 |
| Start date | 1 February 2009 |
| Primary completion | 1 January 2010 |
| Sites | 28 locations across Mexico |
Conditions studied
- Thromboembolism — all drugs for Thromboembolism →
- Arthroplasty, Replacement, Hip — all drugs for Arthroplasty, Replacement, Hip →
Sponsor
Boehringer Ingelheim — full company profile →
Who can join
Adults 18 to 74, any sex, with Thromboembolism or Arthroplasty, Replacement, Hip. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Open, prospective, uncontrolled, observational cohort study.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
New anticoagulants for the prevention of venous thromboembolism.
Becattini C, Lignani A, Agnelli G. · · 2010 · cited 17× · PMID 20531960 · DOI 10.2147/dddt.s6074
Verify or expand the search:
- PubMed search for NCT00967447
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Thromboembolism
Currently open trials in the same condition.
- NCT06657924 — Preoperative Tranexamic Acid (TXA) to Prevent Bleeding in Patients Undergoing Major Colorectal Surgery · Phase 2 · recruiting
- NCT06442267 — Comparing Anticoagulation Strategies Using UFH, Argatroban and LMWH for ECMO Support · Phase 4 · recruiting
- NCT06443905 — Xueshuantong Injection (Lyophilized) in the Prevention of Venous Thromboembolism (VTE) in Hospitalized Patients · active not recruiting
- NCT05301348 — In Vivo Detection of Circulating Clots in Patients With Thromboembolism · NA · recruiting
- NCT06627933 — Optimization of Management in Patients With Cardiovascular Disease After Lower Limb Joint Replacement · recruiting
Other Boehringer Ingelheim trials
Trials by the same sponsor.
- NCT07044700 — Real-world Comparative Effectiveness and Safety of Jardiance in Chinese Patients With Heart Failure of Reduced Ejection · not yet recruiting
- NCT07047508 — Real-world Study to Describe the Effectiveness and Safety Outcomes of Jardiance in Chinese Patients With Heart Failure a · not yet recruiting
- NCT07366034 — A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With I · Phase 3 · not yet recruiting
- NCT07531628 — A Study to Test How Verducatib is Taken up in the Body of Healthy Chinese Participants · Phase 1 · not yet recruiting
- NCT07497087 — A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis · Phase 3 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00967447 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Boehringer Ingelheim
- Last refreshed: 11 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00967447.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing